Glycopyrronium bromide - Hypersalivation in children
You are here : Home > Formulary Search > Glycopyrronium bromide - Hypersalivation in children
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Blue
Formulations :
- Tablets
Formulary Status :
Restrictions / Comments :
Important
Licensed in children 3 years and over. Expensive treatment option - consider an alternative. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team.
Status 2
Blue
Formulations :
- Oral solution
Formulary Status :
Restrictions / Comments :
Important
1mg/5ml oral solution (sugar free). Licensed in children aged 3 years and over. NOTE - different strengths of liquid are not bioequivalent. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team.
Status 3
Blue
Formulations :
- Oral solution
Formulary Status :
Restrictions / Comments :
Important
Oral solution 320mcg/ml (Sialanar brand). Expressed as 400mcg/ml. Licensed in children 3 years and over. NOTE - different strengths of liquid are not bioequivalent. Transfer of prescribing responsibility to primary care after initiation and stabilisation of treatment - minimum of 1 month supply from the specialist team.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Glycopyrronium bromide
Indication :
Hypersalivation in children
Group Name :
Keywords :
excessive saliva, hypersialosis, drooling, sialorrhoea
Brand Names Include :
Assicco, Sialanar
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3
Other Indications
Below are listed other indications that Glycopyrronium bromide is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Hypersalivation in children.
Committee Recommendations (1)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.